Fully characterized, patient-derived xenograft (PDX) model of Non-Small Cell Lung Cancer (NSCLC).
Patient derived tumor xenografts (PDX) are created when cancerous tissue from a patient's primary tumor is implanted directly into an immunodeficient mouse. PDX provides a new approach for preclinical testing of novel anticancer compounds in vivo due to its preservation of key features, which includes invasiveness, stromal reaction, tumor vasculature and cellular diversity of human carcinomas. In contrast to a cell line-xenograft tumor model, PDX tumors are established from the transplantation of fresh tumor tissue from a cancer patient into a immunodeficient mouse. As a result, PDX cancer models are becoming popular models to use in cancer drug research.
From the laboratory of Paul Dent, PhD, Virginia Commonwealth University.
|Product Type:||Cell Line|
|Cell Type:||NSCLC, adenocarcinoma|
|Morphology:||Oviod with projections|
|Subculturing:||Do not subculture under 30%|
|Growth Conditions:||RPMI, 10% FCS|
|Cryopreservation:||Standard with DMSO|
|Age:||74 years old female|
|Comments:||Tumor did not recur in the patient (18 months)|
If you publish research with this product, please let us know so we can cite your paper.